公开(公告)号：US20240350655A1

公开(公告)日：2024-10-24

申请号：US18556602

申请日：2022-04-22

Applicant: FORSCHUNGSVERBUND BERLIN E.V.

Inventor： Christian Ewald STIEGER ,  Christian Peter Richard HACKENBERGER ,  Marc-André KASPER ,  Philipp OCHTROP

IPC: A61K47/68 ,  A61K47/54 ,  C07F9/32 ,  C07F9/6518 ,  C07F9/6524 ,  C07F9/653 ,  C07F9/6558 ,  C07F9/6561

CPC classification number: A61K47/6851 ,  A61K47/548 ,  A61K47/68031 ,  C07F9/3217 ,  C07F9/6518 ,  C07F9/6524 ,  C07F9/65324 ,  C07F9/65583 ,  C07F9/65586 ,  C07F9/6561

Abstract: Disclosed are novel conjugates and methods for the preparation thereof. One of the methods for the preparation of a conjugate comprises a step of: acting a compound of formula (I), with a thiol-containing molecule of formula (II), wherein represents an amino acid, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a saccharide, a polysaccharide, a polymer, a small molecule, an optionally substituted C1-C8-alkyl, an optionally substituted phenyl, or an optionally substituted aromatic 5- or 6-membered heterocyclic system; resulting in a compound of formula (III).

公开(公告)号：US20250049939A1

公开(公告)日：2025-02-13

申请号：US18717535

申请日：2022-12-12

Applicant: TUBULIS GmbH ,  LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN ,  FORSCHUNGSVERBUND BERLIN E.V. ,  Helmholtz Zentrum Muenchen Deutsches forschungszentrum für Gesundheit und Umwelt (GmbH)

Inventor： Heinrich LEONHARDT ,  Andreas STENGL ,  Maike ROAS ,  Jonathan SCHWACH ,  Karsten SPIEKERMANN ,  Harald POLZER ,  Marina ABLE ,  Jonas HELMA-SMETS ,  Dominik SCHUMACHER ,  Marcus GERLACH ,  Christian Peter Richard HACKENBERGER ,  Marc-André KASPER ,  Irmela JEREMIAS ,  Binje VICK ,  Elisabeth KREMMER

IPC: A61K47/68 ,  A61P35/02 ,  C07K16/28

Abstract: The present invention relates to novel anti-FLT3 antibodies for specifically targeting extracellular domain of FLT3. The present invention further relates to targeting FLT3 by novel antibody-drug-conjugates (ADCs) based on the novel anti-FLT3 antibodies of the present invention, especially in combination with kinase inhibitors, for use in therapy and/or for use in a method of cancer treatment (e.g., acute myeloid leukemia (AML) with or without internal tandem duplication (ITD) mutations in the FLT3 gene (FLT3-ITD)).